AMSilk’s bioengineered silk protein yarns debut in Balenciaga Spring 2026 Collection

/in

First commercially available products using AMSilk’s biotech silk protein yarns Demonstrating a scalable, low impact alternative to conventional silk within luxury fashion Designed for resilient, transparent and regionally integrated supply chains Neuried, Germany, January 21, 2026 – AMSilk GmbH (“AMSilk”), a global leader in advanced biomaterials made from silk proteins, today announced that its bioengineered […]

Read more

Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe

/in

The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to BioInnovation Institute (BII), a leading institute for life science and deep tech innovation in Copenhagen. The funding will enable BII to expand its activities into new strategic areas and geographies, and support even more entrepreneurs and start-up-companies, thereby strengthening innovation […]

Read more

AMS: Full Year 2025 Trading Update

/in

~ Strong growth in line with expectations, driven by key surgical product categories ~ Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the innovative tissue-healing medical device company delivering high-performing solutions for better patient outcomes, today announces a trading update for the twelve months ended 31 December 2025. Read more…

Read more

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies

/in

Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of corporate growth Kainova champions scientific agility, bold ambition, and unity of purpose Montreal, Canada, Strasbourg, France, Boston, USA, January 12, 2026: Kainova Therapeutics (“Kainova” or “the Company”), a catalyst for breakthrough treatments for patients in immuno-oncology and inflammation, today announced a transformative rebrand. The new […]

Read more

Seasoned biotherapeutics leader Thomas J. Farrell joins NanoSyrinx as CEO to advance Nanosyringe-enabled intracellular medicines

/in

– 25+ years of biotherapeutics leadership, including serving as founding CEO of two NASDAQ-listed companies and securing over $500 million in funding – Expertise in advanced therapeutics development, driving multiple cell and gene therapy product candidates from discovery through to clinical trials COVENTRY, England, Jan. 8, 2026 /PRNewswire/ — NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, […]

Read more
© Optimum Strategic Communications.